LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2

LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2

Abstract Background Expression of the long non-coding mRNA LINC00152 has been reported to correlate with cancer cell resistance to oxaliplatin (L-OHP). However, little is known regarding the molecular mechanism of LINC00152 in esophageal cancer (EC). Hence, we intended to characterize the role of LI...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international Vol. 20; no. 1; pp. 1 - 569
Main Authors: Zhang, Shuyao, Liao, Wei, Wu, Qinshui, Huang, Xiaoshan, Pan, Zhen, Chen, Wang, Gu, Shuyi, Huang, Zuojun, Wang, Yiwen, Tang, Xu, Liang, Shanshan, Zhang, Xiaoyan, Chen, Yun, Chen, Shuang, Chen, Wanying, Jiang, Yi, Chen, Chen, Qiu, Guodong
Format: Journal Article
Language:English
Published: London BioMed Central 26-11-2020
BMC
Subjects:
Antibodies
Biotechnology industry
Cancer
Cancer therapies
Cell viability
Chemotherapy
Chemotherapy resistance
Cholecystokinin
Colorectal cancer
DNA methylation
Drug resistance
Epithelial-mesenchymal transition
Esophageal cancer
Esophagus
Ethics
Experiments
Gastric cancer
Homeobox
LINC00152
Medical research
Mesenchyme
mRNA
Oxaliplatin
Primary Research
Proteins
Radiation therapy
Zeste Homologue 2
Zinc finger e-box binding homeobox 1
Zinc finger proteins
Beijing China
St Louis Missouri
United Kingdom > UK
United States > US
China
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Expression of the long non-coding mRNA LINC00152 has been reported to correlate with cancer cell resistance to oxaliplatin (L-OHP). However, little is known regarding the molecular mechanism of LINC00152 in esophageal cancer (EC). Hence, we intended to characterize the role of LINC00152 in EC, with a special focus on epithelial-mesenchymal transition (EMT) and L-OHP resistance. Methods We collected EC tissues and identified EC cell lines with higher L-OHP resistance, and then characterized expression patterns of LINC00152, Zeste Homologue 2 (EZH2), Zinc finger e-box binding homeobox (ZEB1) and EMT-related genes using RT-qPCR and Western blot analysis. Furthermore, their functional significance was identified by gain and loss-of-function experiments. The relationship among LINC00152, EZH2 and ZEB1 was examined using RIP, RNA pull-down and ChIP assays. Additionally, resistance of EC cells to L-OHP was reflected by CCK-8 assay to detect cell viability. Animal experiments were also conducted to detect the effects of the LINC00152/EZH2/ZEB1 on EMT and L-OHP resistance. Results LINC00152, EZH2 and ZEB1 were highly expressed in EC tissues and Kyse−150/TE-1 cells. As revealed by assays in vitro and in vivo , LINC00152 positively regulated ZEB1 expression through interaction with EZH2 to enhance EMT and L-OHP resistance in EC cells. In contrast, silencing of LINC00152 contributed to attenuated EMT and drug resistance of EC cells to L-OHP. Conclusions Our study demonstrates that LINC00152/EZH2/ZEB1 axis can regulate EMT and resistance of EC cells to L-OHP, thus presenting a potential therapeutic target for EC treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-020-01620-1